increased risk of death due to stroke with Evista (raloxifene)

Health Canada is warning of increased risk of death due to stroke with Evista (raloxifene).

This applies only to postmenopausal women who already have heart disease or a high risk of stroke.

The warning stems from the results of a new study. But the results are still preliminary.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter Canada includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 300+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get quote